Literature DB >> 21734041

epitopes immediately below the base of the V3 loop of gp120 as targets for the initial autologous neutralizing antibody response in two HIV-1 subtype B-infected individuals.

Haili Tang1, James E Robinson, S Gnanakaran, Ming Li, Eric S Rosenberg, Lautaro G Perez, Barton F Haynes, Hua-Xin Liao, Celia C Labranche, Bette T Korber, David C Montefiori.   

Abstract

Epitopes that drive the initial autologous neutralizing antibody response in HIV-1-infected individuals could provide insights for vaccine design. Although highly strain specific, these epitopes are immunogenic, vulnerable to antibody attack on infectious virus, and could be involved in the ontogeny of broadly neutralizing antibody responses. To delineate such epitopes, we used site-directed mutagenesis, autologous plasma samples, and autologous monoclonal antibodies to map the amino acid changes that led to escape from the initial autologous neutralizing antibody response in two HIV-1 subtype B-infected individuals. Additional mapping of the epitopes was accomplished by using alanine scanning mutagenesis. Escape in the two individuals occurred by different pathways, but the responses in both cases appeared to be directed against the same region of gp120. In total, three amino acid positions were identified that were independently associated with autologous neutralization. Positions 295 and 332 are located immediately before and after the N- and C-terminal cysteines of the V3 loop, respectively, the latter of which affected an N-linked glycan that was critical to the neutralization epitope. Position 415 affected an N-linked glycan at position 413 in the C terminus of V4 that might mask epitopes near the base of V3. All three sites lie in close proximity on a four-stranded antiparallel sheet on the outer domain of gp120. We conclude that a region just below the base of the V3 loop, near the coreceptor binding domain of gp120, can be a target for autologous neutralization.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21734041      PMCID: PMC3165744          DOI: 10.1128/JVI.02286-10

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  101 in total

1.  HIV-1: nature's master of disguise.

Authors:  John R Mascola; David C Montefiori
Journal:  Nat Med       Date:  2003-04       Impact factor: 53.440

2.  HIV-1 evades antibody-mediated neutralization through conformational masking of receptor-binding sites.

Authors:  Peter D Kwong; Michael L Doyle; David J Casper; Claudia Cicala; Stephanie A Leavitt; Shahzad Majeed; Tavis D Steenbeke; Miro Venturi; Irwin Chaiken; Michael Fung; Hermann Katinger; Paul W I H Parren; James Robinson; Donald Van Ryk; Liping Wang; Dennis R Burton; Ernesto Freire; Richard Wyatt; Joseph Sodroski; Wayne A Hendrickson; James Arthos
Journal:  Nature       Date:  2002-12-12       Impact factor: 49.962

3.  Characterization of CD4-induced epitopes on the HIV type 1 gp120 envelope glycoprotein recognized by neutralizing human monoclonal antibodies.

Authors:  Shi-Hua Xiang; Najah Doka; Rabeéa K Choudhary; Joseph Sodroski; James E Robinson
Journal:  AIDS Res Hum Retroviruses       Date:  2002-11-01       Impact factor: 2.205

4.  Antibody neutralization and escape by HIV-1.

Authors:  Xiping Wei; Julie M Decker; Shuyi Wang; Huxiong Hui; John C Kappes; Xiaoyun Wu; Jesus F Salazar-Gonzalez; Maria G Salazar; J Michael Kilby; Michael S Saag; Natalia L Komarova; Martin A Nowak; Beatrice H Hahn; Peter D Kwong; George M Shaw
Journal:  Nature       Date:  2003-03-20       Impact factor: 49.962

5.  Rapid evolution of the neutralizing antibody response to HIV type 1 infection.

Authors:  Douglas D Richman; Terri Wrin; Susan J Little; Christos J Petropoulos
Journal:  Proc Natl Acad Sci U S A       Date:  2003-03-18       Impact factor: 11.205

6.  Viremia control despite escape from a rapid and potent autologous neutralizing antibody response after therapy cessation in an HIV-1-infected individual.

Authors:  David C Montefiori; Marcus Altfeld; Paul K Lee; Miroslawa Bilska; Jintao Zhou; Mary N Johnston; Feng Gao; Bruce D Walker; Eric S Rosenberg
Journal:  J Immunol       Date:  2003-04-01       Impact factor: 5.422

7.  A longitudinal assessment of autologous neutralizing antibodies in children perinatally infected with human immunodeficiency virus type 1.

Authors:  Rebeca Geffin; Cecelia Hutto; Carole Andrew; Gwendolyn B Scott
Journal:  Virology       Date:  2003-06-05       Impact factor: 3.616

8.  The broadly neutralizing anti-human immunodeficiency virus type 1 antibody 2G12 recognizes a cluster of alpha1-->2 mannose residues on the outer face of gp120.

Authors:  Christopher N Scanlan; Ralph Pantophlet; Mark R Wormald; Erica Ollmann Saphire; Robyn Stanfield; Ian A Wilson; Hermann Katinger; Raymond A Dwek; Pauline M Rudd; Dennis R Burton
Journal:  J Virol       Date:  2002-07       Impact factor: 5.103

9.  Oligomeric structure of the human immunodeficiency virus type 1 envelope protein on the virion surface.

Authors:  Rob J Center; Richard D Leapman; Jacob Lebowitz; Larry O Arthur; Patricia L Earl; Bernard Moss
Journal:  J Virol       Date:  2002-08       Impact factor: 5.103

10.  Antibody domain exchange is an immunological solution to carbohydrate cluster recognition.

Authors:  Daniel A Calarese; Christopher N Scanlan; Michael B Zwick; Songpon Deechongkit; Yusuke Mimura; Renate Kunert; Ping Zhu; Mark R Wormald; Robyn L Stanfield; Kenneth H Roux; Jeffery W Kelly; Pauline M Rudd; Raymond A Dwek; Hermann Katinger; Dennis R Burton; Ian A Wilson
Journal:  Science       Date:  2003-06-27       Impact factor: 47.728

View more
  20 in total

Review 1.  The Antibody Response against HIV-1.

Authors:  Julie Overbaugh; Lynn Morris
Journal:  Cold Spring Harb Perspect Med       Date:  2012-01       Impact factor: 6.915

Review 2.  Discovery of protective B-cell epitopes for development of antimicrobial vaccines and antibody therapeutics.

Authors:  Jacqueline Sharon; Michael J Rynkiewicz; Zhaohua Lu; Chiou-Ying Yang
Journal:  Immunology       Date:  2014-05       Impact factor: 7.397

3.  Neutralizing antibody escape during HIV-1 mother-to-child transmission involves conformational masking of distal epitopes in envelope.

Authors:  Leslie Goo; Caitlin Milligan; Cassandra A Simonich; Ruth Nduati; Julie Overbaugh
Journal:  J Virol       Date:  2012-06-27       Impact factor: 5.103

4.  Kinetic mechanism for HIV-1 neutralization by antibody 2G12 entails reversible glycan binding that slows cell entry.

Authors:  Emily J Platt; Michelle M Gomes; David Kabat
Journal:  Proc Natl Acad Sci U S A       Date:  2012-04-30       Impact factor: 11.205

5.  Simian-Human Immunodeficiency Virus SHIV.CH505-Infected Infant and Adult Rhesus Macaques Exhibit Similar Env-Specific Antibody Kinetics, despite Distinct T-Follicular Helper and Germinal Center B Cell Landscapes.

Authors:  Ashley N Nelson; Ria Goswami; Maria Dennis; Joshua Tu; Riley J Mangan; Pooja T Saha; Derek W Cain; Alan D Curtis; Xiaoying Shen; George M Shaw; Katharine Bar; Michael Hudgens; Justin Pollara; Kristina De Paris; Koen K A Van Rompay; Sallie R Permar
Journal:  J Virol       Date:  2019-07-17       Impact factor: 5.103

6.  A potent and broad neutralizing antibody recognizes and penetrates the HIV glycan shield.

Authors:  Robert Pejchal; Katie J Doores; Laura M Walker; Reza Khayat; Po-Ssu Huang; Sheng-Kai Wang; Robyn L Stanfield; Jean-Philippe Julien; Alejandra Ramos; Max Crispin; Rafael Depetris; Umesh Katpally; Andre Marozsan; Albert Cupo; Sebastien Maloveste; Yan Liu; Ryan McBride; Yukishige Ito; Rogier W Sanders; Cassandra Ogohara; James C Paulson; Ten Feizi; Christopher N Scanlan; Chi-Huey Wong; John P Moore; William C Olson; Andrew B Ward; Pascal Poignard; William R Schief; Dennis R Burton; Ian A Wilson
Journal:  Science       Date:  2011-10-13       Impact factor: 47.728

7.  Evolution of an HIV glycan-dependent broadly neutralizing antibody epitope through immune escape.

Authors:  Penny L Moore; Elin S Gray; C Kurt Wibmer; Jinal N Bhiman; Molati Nonyane; Daniel J Sheward; Tandile Hermanus; Shringkhala Bajimaya; Nancy L Tumba; Melissa-Rose Abrahams; Bronwen E Lambson; Nthabeleng Ranchobe; Lihua Ping; Nobubelo Ngandu; Quarraisha Abdool Karim; Salim S Abdool Karim; Ronald I Swanstrom; Michael S Seaman; Carolyn Williamson; Lynn Morris
Journal:  Nat Med       Date:  2012-10-21       Impact factor: 53.440

8.  Early low-titer neutralizing antibodies impede HIV-1 replication and select for virus escape.

Authors:  Katharine J Bar; Chun-yen Tsao; Shilpa S Iyer; Julie M Decker; Yongping Yang; Mattia Bonsignori; Xi Chen; Kwan-Ki Hwang; David C Montefiori; Hua-Xin Liao; Peter Hraber; William Fischer; Hui Li; Shuyi Wang; Sarah Sterrett; Brandon F Keele; Vitaly V Ganusov; Alan S Perelson; Bette T Korber; Ivelin Georgiev; Jason S McLellan; Jeffrey W Pavlicek; Feng Gao; Barton F Haynes; Beatrice H Hahn; Peter D Kwong; George M Shaw
Journal:  PLoS Pathog       Date:  2012-05-31       Impact factor: 6.823

9.  HIV-1 Coreceptor Usage and Variable Loop Contact Impact V3 Loop Broadly Neutralizing Antibody Susceptibility.

Authors:  Ludy Registre; Yvetane Moreau; Sila Toksoz Ataca; Surya Pulukuri; Timothy J Henrich; Nina Lin; Manish Sagar
Journal:  J Virol       Date:  2020-01-06       Impact factor: 6.549

10.  Viral escape from neutralizing antibodies in early subtype A HIV-1 infection drives an increase in autologous neutralization breadth.

Authors:  Megan K Murphy; Ling Yue; Ruimin Pan; Saikat Boliar; Anurag Sethi; Jianhui Tian; Katja Pfafferot; Etienne Karita; Susan A Allen; Emmanuel Cormier; Paul A Goepfert; Persephone Borrow; James E Robinson; S Gnanakaran; Eric Hunter; Xiang-Peng Kong; Cynthia A Derdeyn
Journal:  PLoS Pathog       Date:  2013-02-28       Impact factor: 6.823

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.